November 19, 2026 · Gynecologic oncology reports · DOI: 10.1016/j.gore.2026.102176

Potential role of antibody-drug conjugates in gynecologic cancer patients with brain metastases.

Listen to this summary

This retrospective case series of eight gynecologic cancer patients with brain metastases asks whether antibody-drug conjugates (ADCs), which are typically excluded from trials involving CNS disease, have meaningful intracranial activity and what toxicities they carry. Across 12 ADC regimens, 25% of intracranial responses were partial responses and 58% were stable disease, with radiation necrosis occurring in 2 of 7 patients who had received radiotherapy. The authors conclude that ADCs show feasibility and intracranial activity in this population, and they call for prospective multi-institutional trials to define ADC efficacy and the optimal sequencing of ADCs with radiotherapy.

Eliya Shachar, Stephen S Cai, Jordyn Silverstein, Lorna Kwan, Ritu Salani, Dana Chase, Beth Karlan

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play